Merck & Company vs Thermo Fisher Scientific at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | MRK | TMO |
|---|---|---|
| Market cap | $378.46B | $235.17B |
| Price | $149.54 | $630.70 |
| P/E ratio (TTM) | 14.18 | 32.4 |
| P/B ratio (MRQ) | 4.92 | 4.09 |
| P/S ratio (TTM) | 3.98 | 4.9 |
| Revenue growth (1Y) | 1.31% | 3.91% |
| Return on equity (TTM) | 34.70% | 12.61% |
| Return on invested capital (TTM) | 22.71% | 8.06% |
| Gross margin (TTM) | 82.44% | 40.37% |
| Net margin (TTM) | 13.59% | 15.06% |
| Dividend yield (TTM) | 2.22% | 0.30% |
How they differ
Merck & Company is the larger company at $378.46B versus $235.17B — about 1.6x the size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 32.4 for Thermo Fisher Scientific.
On sales, Merck & Company is the cheaper of the two at 3.98 against 4.9 for Thermo Fisher Scientific.
Thermo Fisher Scientific leads on revenue growth over the past year, 3.91% against 1.31%.
Merck & Company leads on return on invested capital, 22.71% against 8.06%.
Merck & Company leads on gross margin, 82.44% against 40.37%.
Merck & Company offers the higher yield at 2.22% against 0.30%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Merck & Company or Thermo Fisher Scientific.